alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description,gene,cancer_type_raw_text
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_1,LEVEL_Fda2,Anaplastic Large-Cell Lymphoma ALK Positive,,"28032129,29352732,23598171",,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of pediatric patients one year of age and older and young adults with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). FDA approval was based on the multicenter, single-arm ADVL0912 study in 26 patients one to ≤21 years of age with relapsed or refractory, systemic ALK-positive ALCL in which the objective response rate was 88% (95% CI: 71-96), with 21 patients (81%) having a complete response and two patients (8%) having a partial response (PMID: 28032129, 23598171, 29352732).",ALK,"{'id': 336, 'code': 'ALCLALKP', 'color': 'LimeGreen', 'name': 'Anaplastic Large-Cell Lymphoma ALK Positive', 'mainType': {'id': None, 'name': 'Mature T and NK Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'ALCL', 'level': 6, 'tumorForm': 'LIQUID'}"
Fusions,Crizotinib,For patients with ALK-positive inflammatory myofibroblastic tumors (IMT),LEVEL_1,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"20979472,29352732,23598171,28787259",https://ascopubs.org/doi/full/10.1200/PO.18.00297,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of patients with ALK fusion-positive inflammatory myofibroblastic tumors (IMTs). FDA approval was based on the Phase I/II, single-arm trial of fourteen pediatric patients with ALK fusion-positive IMT in which the overall response rate was 86% (12/14 patients; 95% CI: 57-98), with five patients having a complete response and seven patients having a partial response (PMID: 28787259, 23598171). FDA approval was also based on the Phase I, single-arm trial of five adult patients with ALK fusion-positive IMT in which the overall response rate was 71% (5/7 patients), including one patient who had a complete response (PMID: 29352732). The NCCN also recommends crizotinib for ALK fusion-positive IMT based on a case report of a patient with ALK fusion-positive IMT who had a sustained partial response to treatment with crizotinib (PMID: 20979472). A retrospective study of eight IMT patients who were treated with surgery and crizotinib showed partial or complete responses in all patients, and relapse only in two of three patients harboring RANBP2-ALK fusions (Abstract: Trahair et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00297).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,23724913,,"Crizotinib, an oral small molecule inhibitor of ALK, ROS1 and MET, is FDA-approved for the treatment of ALK fusion-positive metastatic non-small cell lung cancer (NSCLC) and is considered standard first-line therapy for these patients. The FDA approval is based on the results of an open-label, Phase III clinical trial in which patients with locally advanced or metastatic lung cancer with ALK rearrangement who had received one prior platinum-based regimen were randomized to either crizotinib (250 mg PO BID) or chemotherapy with pemetrexed (500 mg/m2) or docetaxel (75 mg/m2), with crossover allowed. Crizotinib improved the primary endpoint of progression-free survival (median 7.7 months vs. 3.0 months; hazard ratio for progression or death with crizotinib, 0.49; p<0.001), as well as response rates (65% vs .20%; p=0.001) (PMID: 23724913).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28126333,https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. FDA approval of ceritinib in NSCLC was based on the Phase III, randomized, open-label ASCEND-4 study in which 376 patients with ALK-rearranged NSCLC were randomized to ceritinib (750 mg/day) or chemotherapy (cisplatin [75 mg/m2], or carboplatin [target area under the curve of 5-6] plus pemetrexed [500 mg/m2] every 21 days). Median progression-free survival was 16.6 months (95% CI: 12.6-27.2) in the ceritinib group versus 8.1 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.55 (95% CI: 0.42-0.73; p<0·00001). Overall response was seen in 72.5% of patients in the ceritinib group (137/189) versus 26.7% of patients in the chemotherapy group (50/187). Additionally, subgroup analysis of patients with brain metastases showed a median progression-free survival of 25.2 months (95% CI: 13.9 - not estimable) in the ceritinib group versus 8.3 months (95% CI: 5.8-11.1) in the chemotherapy group, with a hazard ratio of 0.44 (95% CI: 0.31-0.63), suggesting significant benefit of ceritinib in patients with intracranial disease (PMID: 28126333). Additionally, the Phase II ASCEND-7 trial of ceritinib in patients ALK+ NSCLC with measurable intracranial disease demonstrated efficacy of ceritinib in the brain (Abstract: Chow et al. Abstract# 1478O, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ensartinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,34473194,,"Ensartinib is an orally available, small molecule second-generation ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. FDA approval was based on the results of the Phase III eXALT3 (NCT02767804) trial of ensartinib versus crizotinib in 290 patients with ALK-positive NSCLC. 

In the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=143) demonstrated a median progression-free survival (PFS) of 25.8 months (95% CI=21.8-NR), an overall response rate (ORR) of 74% (n=106/143) (95% CI=66-81), with a 12% complete response (CR) rate and 62% partial response (PR) rate, and a median duration of response (DOR) that was not reached (95% CI=22-NR) (PMID: 34473194). Conversely, the crizotinib cohort (n=147) demonstrated a median PFS of 12.7 months (95% CI=9.2-16.6) (HR=0.56 [95% CI=0.40-0.79]; p<0.0007), an ORR of 67% (n=98/147) (95% CI=58-74), with a 5% CR rate and 61% PR rate, and a median DOR of 27.3 months (95% CI=12.9-NR) (PMID: 34473194).

Of patients with baseline measurable central nervous system (CNS) diseases in the Phase III eXALT3 (NCT02767804) trial, the ensartinib cohort (n=17) demonstrated a CNS ORR of 59% (95% CI=33-82), with a 24% CR rate and 35% PR rate, with 30% of responding patients having a DOR over twelve months (PMID: 34473194). The crizotinib cohort (n=24) demonstrated a CNS ORR of 21% (95% CI=7-42), with an 8% CR rate and 13% PR rate, with 40% of responding patients having a DOR over twelve months (PMID: 34473194).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30215676,28586279,38598794,32418886,29668860",,"Alectinib is a second-generation small molecule inhibitor of ALK that is FDA-approved for treatment of patients with metastatic, ALK fusion-positive non-small cell lung cancer who have progressed on crizotinib therapy. Approval was based on the randomized, open-label, Phase III ALEX study of alectinib versus crizotinib as first-line therapy in 303 patients with ALK-positive non-small cell lung cancer (NSCLC) in which the twelve-month event-free survival rate was 64.8% for alectinib and 48.7% for crizotinib (HR: 0.47, p<0.001) (PMID: 28586279, 30215676). Central nervous system (CNS) response in those with measurable CNS disease at baseline was 81% in the alectinib group versus 50% in the crizotinib group demonstrating superior efficacy for alectinib in intracranial disease (PMID: 28586279, 30215676). Updated final results from the Phase III ALEX study of alectinib versus crizotinib showed the median progression-free survival was 34.8 months versus 10.9 months, the median duration of overall survival was 48.2 months versus 23.2 months and the 5-year overall survival rate was 62.5% (95% CI; 54.3-70.8) versus 45.5% (95% CI; 33.6-57.4), respectively (PMID: 32418886). In the Phase III ALUR trial of alectinib versus chemotherapy in 107 patients with ALK-positive, crizotinib-resistant NSCLC, the median progression-free response was 9.6 months with alectinib and 1.4 months with chemotherapy [HR= 0.15 (95% CI: 0.08-0.29); p < 0.001] (PMID: 29668860). In the Phase III ALINA trial of alectinib versus platinum-based chemotherapy in 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC, the alectinib arm (n=130) did not reach a median disease-free survival (DFS) versus the chemotherapy arm (n=127) demonstrating a median DFS of 41.3 months (95% CI; 28.5-NE), for a 76% improvement in DFS (p< 0.0001). The CNS disease-free survival in the alectinib arm was 98.4% (95% CI; 96.1-100) and 85.8% (95% CI; 78.8-92.8) in the chemotherapy arm (PMID: 38598794).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30280657,28475456",,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). FDA approval was based on results of the randomized Phase II ALTA trial of brigatinib in 222 patients with ALK+ non-small cell lung cancer (NSCLC). Overall response rates (ORR) in the two dosing cohorts (90 mg and 180 mg) were 45% (97.5% CI: 34%-56%) and 54% (97.5% CI: 43%-65%), including one and four complete responses, with median progression-free survival of 9.2 months (95% CI: 7.4-15.6) and 12.9 (95% CI: 11.1-NR) months in each arm, respectively. Significant clinical benefit was also observed in patients with brain metastases at baseline, with 42% (95% CI: 23%-63%) and 67% (95% CI: 41%-87%) intracranial ORR in the 90mg and 180mg cohorts, respectively (PMID: 28475456). In the Phase III ALTA-1L trial of brigatinib versus crizotinib in 275 patients with advanced ALK-positive NSCLC who had not previously received ALK inhibitors, the confirmed response rate was 77% in the brigatinib arm and 60% in the crizotinib arm, the twelve-month progression-free survival was 67% in the brigatinib arm versus 43% in the crizotinib arm, and the hazard ratio for progression or death was 0.49 (PMID: 30280657).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"33207094,35605188,27432227,29074098,30413378,30892989",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinase inhibitors (TKIs). FDA approval was based on the results of the Phase II trial of lorlatinib in 215 patients with ALK-positive metastatic NSCLC in which the overall response rate was 48% and the median duration of response was 12.5 months. In patients with measurable brain metastases (n=89), the intracranial response rate was 60%, with a median duration of response of 19.5 months (PMID: 30413378). Responses were seen across various ALK mutations (PMID: 30413378), but most notably in G1202R-mutant tumors, which are resistant to first-generation ALK inhibitors (PMID: 27432227). In the Phase I trial of lorlatinib in patients with NSCLC with ALK or ROS rearrangements, four patients who harbored ALK G1202R mutation in addition to their ALK rearrangements had a clinical response to lorlatinib treatment (PMID: 29074098). In a Phase II clinical trial of lorlatinib in 198 patients with NSCLC, among patients who failed one or more second-generation ALK TKIs, lorlatinib showed greater efficacy in patients with ALK mutations compared to patients without ALK mutations (69% versus 27%), with progression-free survival for patients with ALK mutations significantly longer than for patients without ALK mutations (11 months vs 5.4 months, hazard ratio = 0.47) (PMID: 30892989). In the randomized, controlled Phase III CROWN trial evaluating lorlatinib versus crizotinib in previously untreated patients with advanced ALK-positive NSCLC with or without brain metastases (n=296), median progression-free survival in the lorlatinib arm (n=149) was not reached (95% CI = not reached-not reached) versus 9.3 months (95% CI = 7.6-11.1; p < .0001) with an objective response rate of 76% (95% CI = 68-83) versus 58% (95% CI = 7.6-11.1), respectively (PMID: 33207094). In the post-hoc analysis of the Phase III CROWN trial, median progression-free survival among patients without baseline brain metastases was not reached (95% CI = not reached–not reached) in the lorlatinib group (n=111) versus eleven months (95% CI = 9.0-14.6 months; HR = 0.32, 95% CI = 0.20–0.49; p < .0001) in the crizotinib group (n=107), and the median progression-free survival among patients with baseline brain metastases was not reached (95% CI = 18.2 months–not reached) in the lorlatinib group (n=38) versus 7.2 months (95% CI = 3.7–9.2 months) in the crizotinib group (n=40) (PMID: 35605188).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Tovorafenib,,LEVEL_1,LEVEL_Fda2,"Low-Grade Glioma, NOS",,37978284,,"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF fusion subcohort (n=64 [KIAA1549-BRAF fusion, n=56; other BRAF duplication or rearrangement by FISH, n=8]) demonstrated an ORR of 52% (95% CI=39-64) and a median DOR of 13.8 months (95% CI=11.3-NE) (PMID: 37978284).",BRAF,"{'id': 259, 'code': 'LGGNOS', 'color': 'Gray', 'name': 'Low-Grade Glioma, NOS', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,,https://www.sciencedirect.com/science/article/pii/S0006497121023806,"Pemigatinib is a small molecule inhibitor of FGFR1-3 which is FDA-approved for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements. FDA approval was based on the results of the Phase II Fight-203 study of pemigatinib in 28 patients with myeloid/lymphoid neoplasms (MLNs) harboring FGFR1-fusions in which 22 of 28 patients (79%; 95% CI= 59-92) had a complete cytogenetic response, including three patients without evidence of morphologic disease (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!). Fourteen of eighteen patients with chronic phase in the marrow with or without extramedullary disease had a complete response to pemigatinib (78%, 95% CI= 52-94). Additionally, two of four patients (50%) with blast phase in the marrow with or without extramedullary disease had a complete response, and one of three patients (33.3%) with extramedullary disease had a complete response following treatment (Abstract: Gotlib et al. Abstract# 634, ASH 2021. https://www.sciencedirect.com/science/article/pii/S0006497121023806#!).",FGFR1,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Pemigatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,32203698,,"Pemigatinib, a small molecule inhibitor of the FGFR kinases, is FDA-approved for the treatment of adults with previously treated, advanced cholangiocarcinoma with an FGFR2 fusion or other FGFR2 rearrangement. FDA approval was based on the results of the Phase II FIGHT-202 trial of pemigatinib in 107 patients with cholangiocarcinoma harboring an FGFR2 fusion or FGFR2 rearrangement in which the overall response rate was 35.5% (38/107; 95% CI=26.5 - 45.4), the disease control rate was 82% (88/107; 95% CI= 74-89), the median progression-free survival was 6.9 months (95%CI= 6.2-9.6) and the median overall survival was 21.1 months (95% CI= 14.8-NE) (PMID: 32203698). Of the patients who responded, three patients had a complete response (2.8%), 35 patients had a partial response (32.7%) and 50 patients had stable disease (46.67%) (PMID: 32203698).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Futibatinib,,LEVEL_1,LEVEL_Fda2,Cholangiocarcinoma,,"34551969,36652354",,"Futibatinib is a pan-FGFR inhibitor that is FDA-approved for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. FDA approval was based on the results of the single-arm phase II FOENIX-CCA2 study of futibatinib in 103 patients with FGFR2-rearranged cholangiocarcinoma in which the overall response rate was 42% (95% CI= 32, 52), with all 43 responders having a partial response, the median progression-free survival was 9.0 months, and overall survival was 21.7 months (PMID: 36652354). In a phase I dose-expansion trial of futibatinib in 43 patients with FGFR2-rearranged cholangiocarcinoma, the objective response rate was 25.4% (PMID: 34551969).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Leukemias of Ambiguous Lineage,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with MPAL, the CR plus CRh rate was 50% (n=1) (PMID: 39121437).",KMT2A,"{'id': 734, 'code': 'ALAL', 'color': 'LightSalmon', 'name': 'Acute Leukemias of Ambiguous Lineage', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,Acute Myeloid Leukemia,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with AML, the CR plus CRh rate was 21% (n=18) (PMID: 39121437).",KMT2A,"{'id': 527, 'code': 'AML', 'color': 'LightSalmon', 'name': 'Acute Myeloid Leukemia', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Revumenib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,39121437,,"Revumenib is an orally available, small-molecule menin inhibitor that is FDA-approved for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. FDA approval is based on the results of the Phase I/II AUGMENT-101 (NCT04065399) trial of revumenib in 104 patients with relapsed or refractory (R/R) acute leukemia (n=86, acute myeloid leukemia [AML]; n=16, acute lymphoblastic leukemia [ALL]; n=2, mixed phenotype acute leukemia [MPAL]) with a KMT2A translocation (n=23, t(9;11) (p22;q23); n=20, t(11;19) (q23;p13); n=10, t(10;11) (p12;q23); n=10, t(6;11) (q27;q23); n=7, t(4;11) (q21;q23); n=3, t(1;11); n=2, t(11;17); n=2, t(11;22); n=1, t(11;16); n=26, fusion partner unknown). In the Phase I/II AUGMENT-101 (NCT04065399) trial, the complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 21.2% (n=22) (95% CI=13.8-30.3), with a median duration of CR plus CRh response of 6.4 months (95% CI=2.7-NE) (PMID: 39121437). The CR rate was 12.5% (95% CI=6.8-20.4), with a median duration of CR response of 4.3 months (95% CI=1.0-NE), and the CRh rate was 8.7% (95% CI=4.0-15.8), with a median duration of CRh response of 6.4 months (95% CI=1.9-NE) (PMID: 39121437). Of patients with ALL, the CR plus CRh rate was 19% (n=3) (PMID: 39121437).",KMT2A,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive NSCLC (n=94 [n=53, CD74-NRG1; n=19, SLC3A2-NRG1; n=10, SDC4-NRG1; n=2, CDH1-NRG1; n=1, CCT6B-NRG1; n=1, FUT10-NRG1; n=1, PVALB-NRG1; n=1, SLC34A2-NRG1; n=1, ST14-NRG1; n=1, VAMP2-NRG1; n=1, ZFAT-NRG1]) demonstrated an overall response rate (ORR) of 31% (95% CI=22-41), with a 1% (n=1) complete response (CR) rate, 30% (n=28) partial response (PR) rate and 43% (n=40) stable disease (SD) rate, and a median duration of response (DOR) of 13.4 months (range=1.9+ to 29.5+) (PMID: 39908431).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_1,LEVEL_Fda2,Pancreatic Adenocarcinoma,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. FDA approval is based on the results of the Phase I/II eNRGy study (NCT02912949) of zenocutuzumab in patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949), patients with NRG1 fusion-positive pancreatic adenocarcinoma (n=36 [n=16, ATP1B1-NRG1; n=4, APP-NRG1; n=3, SLC4A4-NRG1; n=3, CD44-NRG1; n=3, NOTCH2-NRG1; n=2, VTCN1-NRG1; n=1, CDH1-NRG1; n=1, AGRN-NRG1; n=1, SDC4-NRG1; n=1, THBS1-NRG1; n=1, ASPH-NRG1]) demonstrated an overall response rate (ORR) of 44% (95% CI=28-62), with a 3% (n=1) complete response (CR) rate, 42% (n=15) partial response (PR) rate and 36% (n=13) stable disease (SD) rate, and a median duration of response (DOR) of 9.1 months (range=1.9+ to 16.6) (PMID: 39908431).",NRG1,"{'id': 180, 'code': 'PAAD', 'color': 'Purple', 'name': 'Pancreatic Adenocarcinoma', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': 'PANCREAS', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI: 48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI: 19.9-30.9), the median progression-free survival was 28.0 months (95% CI: 15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Larotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"29466156,26216294",,"Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. FDA approval was based on the results of three studies of phase I and II clinical trials in which of 55 patients evaluated with TRK fusions (NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners) in seventeen different cancers, there was an overall response rate of 75% (95% CI= 61%-85%), per RECIST v1.1 criteria (PMID: 29466156). Responses were ongoing in 38/44 (86%) patients; the longest responder remained on treatment at 27+ months. The median duration of response and progression-free survival were not reached at the time of publication (PMID: 29466156). Responses to larotrectinib occur independently of tumor type and NTRK isoform and additional individual case studies of patient responses have been published (PMID: 26216294).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,,https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext,"Repotrectinib is an orally administered, small molecule ROS1/NTRK tyrosine kinase inhibitor that is FDA-approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion and are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, or have progressed following treatment or have no satisfactory alternative therapy. FDA approval was based on the results of the Phase II TRIDENT-1 (NCT03093116) trial of repotrectinib in 88 TKI-naive (n=40) and TKI-pretreated (n=48) patients with NTRK fusion-positive advanced solid tumors (non-small cell lung cancer = 52% TKI-naive, 29% TKI-pretreated; salivary gland cancer = 8% TKI-naive, 17% TKI-pretreated; thyroid cancer = 12% TKI-naive, 8% TKI-pretreated; soft tissue sarcoma = 8% TKI-naive, 12% TKI-pretreated; other = <10% each). In the Phase II TRIDENT-1 (NCT03093116) trial, the TKI-naive cohort demonstrated a confirmed objective response rate (cORR) of 58% (95% CI=41-73), a twelve-month duration of response (DOR) rate of 86% (95% CI=71-100) and a twelve-month progression-free survival (PFS) rate of 56% (95% CI=40-72) while the TKI-pretreated cohort demonstrated a cORR of 50% (95% CI=35-65), a twelve-month DOR rate of 39% (95% CI=16-62) and a twelve-month PFS rate of 22% (95% CI=8-36) (Abstract: Solomon, BJ. Abstract #1372P, Annals of Oncology Vol 34, Suppl 2, 2023. https://www.annalsofoncology.org/article/S0923-7534(23)03242-8/fulltext).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"28183697,38171156","https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407,https://meetinglibrary.asco.org/record/155954/abstract,https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. FDA approval was based on the results of three multicenter, single-arm, clinical trials. In two Phase I clinical trials conducted in a cohort of 119 patients with diverse solid tumors displaying molecular alterations involving NTRK1/2/3, ROS1 or ALK, treatment with entrectinib showed clinical responses only in patients that were naive to prior treatment with inhibitors targeting these genes, such as crizotinib, ceritinib or alectinib. Three of three patients with NTRK1/2/3-rearranged advanced solid tumors responded to entrectinib; durations of response were 2.6 months, 4.6 months and 15.1 months, respectively. Additionally, in two patients with central nervous system (CNS) tumors, entrectinib demonstrated potent activity as evidenced by a complete intracranial response achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer and a substantial reduction in disease burden in an additional patient with a glioneuronal tumor harboring an NTRK1 rearrangement (PMID: 28183697). At a later evaluation, the overall response rate of the trials was 57.4% (95% CI= 43.2 - 70.8), including four (7.4%) complete responses, with an overall median duration of response of 10.4 months and median overall survival of 20.9 months (95% CI= 14.9 - NR) (Abstract: Demetri et al. Abstract# LBA17, ESMO 2018 Congress. https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583)(Abstract: Rolfo et al. Abstract# 65P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407). Two patients with pancreatic cancer harboring NTRK fusions who were treated with entrectinib had clinical improvement lasting for more than one year (Abstract: Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018. https://meetinglibrary.asco.org/record/155954/abstract). In an analysis of the ALKA-372-001, STARTRK-1 and STARTRK-2 trials of entrectinib with 51 evaluable patients with NTRK1/2/3-rearranged non-small cell lung cancer, the objective response rate was 62.7% (95% CI=48.1-75.9), with six complete and 26 partial responses, the median duration of response was 27.3 months (95% CI=19.9-30.9), the median progression-free survival was 28.0 months (95% CI=15.7-30.4) and the median overall survival was 41.5 months (PMID: 38171156).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"12944919,17555450,12660384,16498388,14504092,16845659,18950453,15034867",,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Various PDGFRA fusions have been detected in patients with hematopoietic disease including chronic myeloid leukemia (CML), myeloproliferative disease (MPD), B-cell acute lymphoblastic leukemia (B-ALL), chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES). These fusions include FIP1L1- PDGFRA (PMID: 12660384, 14504092, 18950453), STRN-PDGFRA (PMID: 17555450), ETV6-PDGFRA (PMID: 17555450), KIF5B-PDGFRA (PMID: 16498388), CDK5RAP2-PDGFRA (PMID: 16845659) and BCR-PDGFRA (PMID:12944919, 15034867). Various individual case reports have demonstrated the sensitivity of these fusions to imatinib, as patients with MDS/MPD harboring PDGFRA fusions have had clinical responses, including complete hematological responses and complete molecular responses, upon treatment with imatinib (PMID: 14504092, 12660384, 17555450, 16498388, 16845659, 12944919, 15034867, 18950453).",PDGFRA,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Imatinib,Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.,LEVEL_1,LEVEL_Fda2,Myelodysplastic/Myeloproliferative Neoplasms,,"16960151,12676775,12181402,14504092,18950453,24687085,22897847,26355392,1516603",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151).",PDGFRB,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,All Solid Tumors,,"36108661,38039431",,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for RET fusion-positive solid tumors. FDA approval was based on the results from the Phase I/II LIBRETTO-001 trial of selpercatinib in 41 patients with RET fusion-positive solid tumors other than non-small cell lung cancer and thyroid cancer in which the overall response rate was 44% (95% CI= 28-60) with 4.9% of patients achieving complete response and 39% of patients achieving a partial response (PMID: 36108661). Responses were seen across tumor types including pancreatic (six of eleven patients), colorectal (two of ten patients) and salivary (two of four patients), among others (PMID: 36108661). In a case report, two patients with RET fusion-positive metastatic pancreatic cancer were treated with selpercatinib and both demonstrated sustained disease control with significant reduction in the sum of lesion diameter (PMID: 38039431).",RET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Medullary Thyroid Cancer,,"37870969,32846061",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is an orally available, small molecule RET tyrosine kinase inhibitor (TKI) that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), as detected by an FDA-approved test, who require systemic therapy. RET mutations (single nucleotide variants, multiple nucleotide variants and deletions) for treatment with selpercatinib are detected by the Oncomine Dx Target Test. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128), the Phase III LIBRETTO-531 (NCT04211337) and the Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET-mutant MTC. 

In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 143 patients with advanced or metastatic RET-mutant MTC who had either been previously treated with cabozantinib and/or vandetanib (n=55 [n=33, RET M918T; n=5, RET V804M/L; n=7, RET extracellular cysteine mutation; n=10, RET other mutations]) or were naïve to cabozantinib and vandetanib (n=88 [n=49, RET M918T; n=6, RET V804M/L; n=20, RET extracellular cysteine mutation; n=13, RET other mutations]), the previously treated cohort demonstrated an independently reviewed overall response rate (ORR) of 69% (95% CI=55-81), with a 9% (n=5) complete response (CR) rate, 60% (n=33) partial response (PR) rate and 26% (n=14) stable disease (SD) rate, a one-year progression-free survival (PFS) rate of 82.3% (95% CI=68.7-90.4) and a median duration of response (DOR) that was not evaluable (95% CI=19.1-NE) (PMID: 32846061). In contrast, the treatment-naïve cohort demonstrated an independently reviewed ORR of 73% (95% CI-62-82), with an 11% (n=10) CR rate, 61% (n=54) PR rate and 23% (n=20) SD rate, a one-year PFS rate of 92.4% (95% CI=82.1-96.8) and a median DOR of 22.0 months (95% CI=NE-NE) (PMID: 32846061). 

In the Phase III LIBRETTO-531 (NCT04211337) trial of selpercatinib versus physicians' choice of cabozantinib or vandetanib in 291 adult and adolescent patients with TKI-naïve advanced or metastatic RET-mutant MTC, the selpercatinib treatment group (n=193 [n=121, RET M918T; n=72, RET other mutations]) demonstrated an ORR of 69.4% (95% CI=62.4-75.8), with a 57.5% PR rate, 11.9% CR rate, 20.2% SD rate and 2.1% progressive disease (PD) rate, and a median PFS that was not reached, while the control treatment group (n=98 [n=61, RET M918T; n=37, RET other mutations]) demonstrated an ORR of 38.8% (95% CI=29.1-49.2), with a 34.7% PR rate, 4.1% CR rate, 49.0% SD rate and 1.0% PD rate, and a median PFS of 16.8 months (95% CI=12.2-25.1) (HR=0.28 [95% CI=0.16-0.48], P=0.001) (PMID: 37870969). 

In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET-mutant MTC patients, the ORR was 73% (95% CI=62-82), with an 11% CR rate and 61% PR rate, and the median DOR rate was 22.0 months (95% CI=NE-NE), with 61% of responders remaining in response at six months (Abstract: Morgenstern et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,"32846061,39094065",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022,"Selpercatinib is a small molecule kinase inhibitor of the RET tyrosine kinase receptor that is FDA-approved for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, who are radioactive iodine-refractory or who have progressed on or following prior systemic treatment. FDA approval was based on the results of the Phase I/II LIBRETTO-001 (NCT03157128) and Phase I/II LIBRETTO-121 (NCT03899792) trials of selpercatinib in adult and pediatric patients with advanced RET fusion-positive MTC. In the Phase I/II LIBRETTO-001 (NCT03157128) trial of selpercatinib in 19 patients with RET fusion-positive thyroid cancer (n=9, CCDC6-RET fusion; n=6, NCOA4-RET fusion; n=4, other RET fusion), the independently reviewed objective response rate (ORR) was 79% (95% CI=54-94), with a 5% (n=1) complete response (CR) rate, 74% (n=14) partial response (PR) rate and 21% (n=4) stable disease rate, the one-year progression-free survival (PFS) rate was 64.4% (95% CI=33.0-80.6) and the median duration of response (DOR) was 18.4 months (95% CI=7.6-NE) (PMID: 32846061). In the Phase I/II LIBRETTO-121 (NCT03899792) trial of selpercatinib in 27 pediatric and adolescent patients with RET-altered solid tumors (n=14, RET-mutant MTC; n=10, RET fusion-positive papillary thyroid cancer; n=3, other), in the overall cohort the blinded independent review committee ORR was 48% (95% CI=28-69) and the median DOR rate was not reached (95% CI=NE-NE), with 92% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). Of the RET fusion-positive thyroid cancer patients, the ORR was 60% (95% CI=26-88), with a 30% CR rate and 30% PR rate, and the median DOR rate was not reached (95% CI=NE-NE), with 83% of responders remaining in response at twelve months (Abstract: Morgenstern, DA. et al. Abstract# 10022, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10022). In the long-term efficacy analysis of the Phase I/II LIBRETTO-001 (NCT03157128) trial in 324 patients with RET-mutant medullary thyroid cancer and 66 patients with RET fusion-positive thyroid cancer, patients with treatment-naïve thyroid cancer demonstrated an ORR of 95.8% (95% CI=78.9-99.9), with a 20.8% (n=5) CR rate, 75% (n=18) PR rate and 4.2% (N=1) SD rate, a median PFS that was not reached (95% CI=44.2-NE), three-year PFS rate of 87.3% (95% CI=56.-96.8) and a three-year overall survival rate of 94.4% (95% CI=66.6-99.2) (PMID: 39094065).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Thyroid Cancer,,29657135,"https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109","Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA approval was based on the results of the multicenter, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in nine patients with RET fusion-positive metastatic thyroid cancer, in which the overall response rate was 89% (95% CI= 52-100) and, of the eight patients for whom duration of response (DOR) was evaluated, DOR of more than six months was achieved in 100% (Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy)(PMID: 29657135)(Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109).",RET,"{'id': 898, 'code': '', 'color': 'Teal', 'name': '', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Selpercatinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"36122315,37870973,32846060",https://www.jto.org/article/S1556-0864(19)30742-7/fulltext,"Selpercatinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive solid tumors. FDA approval was based on the results of the multicenter, open-label, multi-cohort LIBRETTO-001 trial (NCT03157128) of selpercatinib in 144 patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who were either previously treated with platinum-based chemotherapy (n = 105 patients) or were treatment naïve (n = 39), in which the overall response rates were 64% (95% CI= 54-73) and 85% (95% CI=70-94) respectively, and duration of response over six months was achieved in 81% and 58% of each cohort, respectively (Abstract: Drilon et al. Abstract# PL02.08, IASCL 2019. https://www.jto.org/article/S1556-0864(19)30742-7/fulltext) (PMID: 32846060). In an updated analysis of the LIBRETTO-001 trial, the overall response rate was 61.1% (95% CI= 54.7%-67.2%) in the platinum-treated group ( n=247) and 84.1% (95% CI=73.3%-91.8%) in the treatment-naive group (n=69) (PMID: 36122315). In the Phase III LIBRETTO-431 trial of selpercatinib versus a control treatment that consisted of platinum-based chemotherapy with pembrolizumab in 212 patients with advanced RET fusion-positive NSCLC, the selpercatinib treated group (n=129) demonstrated an objective response rate of 84% (95% CI=76, 90) and a median progression-free survival of 24.8 months (95% CI=16.9, NE), while the control treatment group (n=83) demonstrated an objective response rate of 65% (95% CI=54, 75) and a median progression-free survival of 11.2 months (95% CI=8.8, 16.8) (HR=0.46 [95% CI=0.31 to 0.70], P=0.001) (PMID: 37870973).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Pralsetinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109,"Pralsetinib is a small molecule kinase inhibitor of the RET receptor tyrosine kinase that is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the multicenter, non-randomized, open-label, multi-cohort ARROW trial (NCT03037385) of pralsetinib in 114 patients with RET fusion-positive metastatic NSCLC (n = 87 patients previously treated with platinum chemotherapy, n = 27 treatment-naïve patients), in which the overall response rate was 57% (95% CI= 46-68) for the previously treated cohort and 70% (95% CI= 50-86) for the treatment-naïve cohort. Duration of response (DOR) was measured in 50 of 87 previously treated patients and 19 of 27 treatment-naïve patients, for which 80% and 58% of these groups had a DOR greater than six months, respectively (Abstract: Subbiah et al. Abstract# 109, ASCO 2020. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109). In the updated data from the ARROW trial with 237 patients with RET fusion-positive metastatic NSCLC, the overall response rate was 78% (95% CI= 68-85) with a median duration of response of 13.4 months (95% CI= 9.4-23.1) in the treatment-naïve patients and 63% (95% CI= 54-71) and 38.8 months (95% CI= 14.8-not estimable) in the previously treated cohort (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=SPGA+-+FDA+Alert+-+08.09.2023&utm_term=View+full+prescribing+information+for+Gavreto).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"30980071,25264305,29596029",,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Taletrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,40179330,,"Taletrectinib is an orally available, small-molecule ROS1/ NTRK tyrosine kinase inhibitor (TKI) that is FDA-approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of the Phase I TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials of taletrectinib in patients with ROS1-positive NSCLC. 
In the Phase II TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, TKI-naїve patients (n=160) demonstrated an objective response rate (ORR) of 88.8% (95% CI=82.8-93.2), with eight complete responses (CR), 134 partial responses (PR) and ten patients demonstrating stable disease (SD), a disease control rate (DCR) of 95.0% (95% CI=90.4-97.8) and a median duration of response (DOR) of 44.2 months (95% CI=30.4-NR) (PMID: 40179330). Patients that were pretreated with a ROS1 TKI (n=113) demonstrated an ORR of 55.8% (95% CI=46.1-65.1), with five CRs, 58 PRs and 36 patients demonstrating stable disease, a DCR of 87.6% (95% CI=80.1-93.1) and a median DOR of 16.6 months (95% CI=10.6-27.3) (PMID: 40179330).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Entrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28183697,"https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract,https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397","Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Repotrectinib,,LEVEL_1,LEVEL_Fda2,Non-Small Cell Lung Cancer,,,https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext,"Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"11287973,24441288,12200353",,"Imatinib is a small molecule inhibitor of BCR-ABL kinase (Philadelphia chromosome; Ph+) FDA-approved for the treatment of adult patients with relapsed or refractory Ph+ chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) and for the treatment of newly diagnosed pediatric Ph+ ALL. In a Phase II trial of imatinib in 48 adult patients with Ph+ ALL, 60% had hematologic response to imatinib treatment, including nine patients with a complete hematologic response, five patients with a marrow complete response, and fifteen patients with a partial marrow response (PMID: 12200353). In an earlier dose-escalation study of imatinib in Ph+ CML or ALL, of twenty patients with Ph+ ALL in blast crisis, 70% of patients exhibited a response to treatment, including four patients who had a complete response to treatment (PMID: 11287973). A five-year follow up study on imatinib in Ph+ pediatric ALL demonstrated that the five-year event-free survival rates for imatinib treatment and bone marrow transplant were 70% and 58%, respectively (PMID: 24441288).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Imatinib,"1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"11287973,28095277,12637609,11287972",,"Imatinib is an orally bioavailable inhibitor of the BCR-ABL fusion protein (Philadelphia chromosome; Ph+) that is FDA-approved in Ph+ chronic myeloid leukemia (CML). In a Phase I dose escalation trial of adult patients with Ph+ CML who had failed front-line interferon-alpha therapy, imatinib treatment induced a complete hematologic response in 98% of treated patients, including a major cytogenetic response in 31% of patients (17 of 54) and a complete cytogenetic response in 14% of patients (7 of 54) (PMID: 11287972). In another study of patients with Ph+ CML, imatinib treatment led to a response in 55% of patients in myeloid blast crisis and 70% of patients in lymphoid blast crisis (PMID: 11287973). In a Phase III trial of imatinib versus interferon in combination with low-dose cytarabine in patients with Ph+ CML, higher rates of complete response (95.3% vs. 55.5%, p < 0.001) and progression-free-survival at one year (96.6% vs. 79.9%, p < 0.001) were seen in the imatinib group versus the combination therapy group, respectively (PMID: 12637609). More recent data from the STIM1 study has suggested that treatment with imatinib can be stopped in certain patients who have received imatinib for at least 2 years and have achieved specific predetermined criteria (PMID: 28095277).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"17496201,20131302,21931113",http://www.bloodjournal.org/content/130/Suppl_1/98,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of adult and pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to prior therapy. FDA approval was based on Phase II and Phase III studies of dasatinib in adult patients with imatinib-resistant Ph+ ALL in which major hematologic responses were seen in 38%-42% of patients (PMID: 17496201, 20131302). In a Phase II study of first-line dasatinib in adult patients with Ph+ ALL, the median overall survival and median disease-free survival were 30.8 and 21.5 months, respectively, with molecular response to dasatinib correlated to disease-free survival (PMID: 21931113), suggesting that dasatinib also has efficacy in the kinase-inhibitor-naive setting. Approval for pediatric patients with Ph+ ALL was based on the Phase II CA180-372 study of 78 pediatric patients with B-cell precursor Ph+ ALL of which there was an event-free survival (EFS) rate of 64.1% (95% CI = 52.4-74.7) (Abstract: Hunger et al. ASH 2017. http://www.bloodjournal.org/content/130/Suppl_1/98).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,"1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib",LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"20525993,23502220,28218239",,"Nilotinib is a second-generation small molecule inhibitor of BCR-ABL that has increased binding and specificity compared to imatinib and is FDA-approved for the treatment of pediatric or adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML). In a Phase III study of nilotinib versus imatinib in 846 patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, the rate of major molecular response was significantly higher in patients receiving nilotinib at either of two doses versus imatinib (43-44% vs. 22%, p < 0.001), as was the rate of complete cytogenetic response (78-80% vs. 65%, p < 0.001) (PMID: 20525993). Importantly, an analysis conducted at the three-year follow-up of patients from this study found significantly fewer ABL1 secondary mutations in patients treated with either dose of nilotinib versus those treated with imatinib, suggesting that nilotinib may prevent the majority of acquired ABL1 secondary resistance mutations that stem from BCR-ABL tyrosine kinase inhibition and may prolong treatment responses to BCL-ABL inhibition (PMID: PMID: 23502220). More recent data from the Phase II ENESTop and ENESTfreedom studies have suggested that treatment with nilotinib can be stopped in certain patients who have received nilotinib for at least three years and have achieved specific predetermined criteria, a recommendation which is now included on the FDA label for nilotinib (PMID: 28218239).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Dasatinib,For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"27217448,20525995",,"Dasatinib, a potent, orally available small molecule inhibitor of the ABL1 and SRC family of kinases, is FDA-approved for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In a Phase III study of imatinib versus dasatinib in 519 patients with newly diagnosed Ph+ CML in chronic phase, the complete cytogenetic response rate was significantly higher in the dasatinib arm versus the imatinib arm at twelve months (77% vs. 66%, p = 0.007), as was the rate of major molecular response (52% vs. 34%, p < 0.0001) (PMID: 20525995). In a five-year follow-up of that study, patients given dasatinib still had significantly higher rates of complete cytogenetic response and major molecular response, with rates of overall survival and progression-free survival of 91% and 86%, respectively (PMID: 27217448).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"29091516,24345751,26040495",https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017,"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is FDA-approved for adult patients with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. FDA approval was based on the results of a Phase III, two-arm, open-label, randomized, multicenter trial (NCT02130557) of bosutinib (n = 246 patients) versus imatinib (n = 241 patients) in 487 eligible adult patients with newly diagnosed CP Ph+ CML in which the major molecular and complete cytogenetic responses by month twelve were 47.2% (95% CI: 40.9, 53.4) and 77.2% (95% CI: 72.0, 82.5) in the bosutinib group, respectively, and 36.9% (95% CI: 30.8, 43.0) and 66.4% (95% CI: 60.4, 72.4) in the imatinib group, respectively (PMID: 29091516). In a separate single-arm, open-label, multicenter study (NCT00261846) designed to evaluate the efficacy and safety of bosutinib in 506 evaluable patients with Ph+ CML who were resistant or intolerant to prior therapy, 59.5% (95% CI: 53.3, 65.5) of the 262 evaluable patients with Ph+ CP CML who had prior treatment with imatinib achieved a major cytogenetic response at any time compared to 40.2% (95% CI: 31.0, 49.9) of the 112 patients with Ph+ CP CML who were treated with imatinib plus at least one additional TKI (PMID: 24345751, 26040495). Furthermore, 30.6% (95% CI: 20.2, 42.5) of the 72 patients with AP CML achieved complete hematologic response by week 48 compared to the 16.7% (95% CI: 8.3, 28.5) of 60 patients with BP CML (PMID: 24345751, 26040495). FDA approval of bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML that is newly diagnosed or resistant or intolerant to prior therapy was based on the results of the BCHILD trial (NCT04258943). For newly diagnosed patients at 6 and 12 months the cumulative incidence of major cytogenetic response (MCyR) was 85% (95% CI: 49, 96) and 92.5% (95% CI: 39, 99), complete cytogenetic response (CCyR) was 77% (CI: 47, 91) and 88.3% (95% CI: 55, 98), and major molecular response (MMR) was 23% (95% CI: 7, 46) and 30% (95% CI: 10, 54), respectively (Abstract: Pennesi et al. Abstract # 10017, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10017).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Asciminib,,LEVEL_1,LEVEL_Fda2,Chronic Myelogenous Leukemia,,"34407542,38820078",,"Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) small molecule inhibitor of the BCR-ABL1 protein that is FDA-approved for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and previously-treated Ph+ CML in CP, with or without the T315I mutation. FDA approval was based on the results of the Phase III ASC4FIRST (NCT04971226) trial for newly diagnosed Ph+ CML in CP and the Phase III CABL001A2301 (NCT03106779) trial for previously diagnosed Ph+ CML in CP. 

In the Phase III ASC4FIRST (NCT04971226) trial of asciminib versus investigator-selected tyrosine kinase inhibitors (TKI) (imatinib, nilotinib, dasatinib or bosutinib) in 405 patients with newly diagnosed Ph+ CML in CP, the asciminib cohort (n=201) demonstrated a major molecular response (MMR) rate at week 48 of 67.7% (n=136) (95% CI=61-74) (PMID: 38820078). In contrast, the investigator-selected TKI cohort (n=204 [n=102, imatinib; n=102, second-generation TKI]) demonstrated an MMR rate at week 48 of 49.0% (n=100) (95% CI=42-56) (treatment difference=18.9% [95% CI=9.6-28.2]; p<0.001) (PMID: 38820078). 

In the Phase III CABL001A2301 (NCT03106779) trial of asciminib versus bosutinib in 233 patients with Ph+ CML previously treated with two or more TKIs, the asciminib cohort (n=157) had an MMR rate of 25% (95% CI=19-33) and a complete cytogenetic response (MCyR) rate of 41% (95% CI=31-51) (PMID: 34407542). In contrast, the bosutinib cohort (n=76) demonstrated an MMR rate of 13% (95% CI=6.5-23) and an MCyR rate of 24% (95% CI=14-37) (PMID: 34407542).",bcr-abl1,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Ponatinib,,LEVEL_1,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,24180494,,"Ponatinib is a small molecule kinase inhibitor of the BCR-ABL fusion that is FDA-approved for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. FDA approval was based on the results of a single-arm, open-label, international, multicenter trial (NCT01207440) of ponatinib in 32 eligible patients with Ph+ALL in which the major and complete hematologic responses were 41% (95% CI: 24, 59) and 34% (95% CI:19, 53), respectively (PMID: 24180494).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
COL1A1-PDGFB Fusion,Imatinib,"Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans",LEVEL_1,LEVEL_Fda2,Dermatofibrosarcoma Protuberans,,"20439456,21128251,15503291,15746584,18451237,15681532,19620561",,"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), a cutaneous soft-tissue sarcoma characterized by a translocation that results in the fusion of the PDGFB gene to the COL1A1 gene (PMID: 21128251). Several studies and case reports have documented patients with DFSP deriving clinical benefit from imatinib treatment (PMID: 15503291, 15746584, 15503291, 19620561, 20439456). In a clinical study of imatinib in eight patients with DFSP harboring the PDGFB-COL1A1 fusion, four of eight patients (50%) had complete clinical responses, and one of eight patients (12.5%) had a partial response to imatinib treatment (PMID: 15681532). Additionally, in a Phase II trial of imatinib in malignancies with KIT/PDGFRA/PDGFRB alterations, ten of eleven evaluable patients with PDGFB-altered DFSP responded to treatment with imatinib, with four of eleven patients having a complete response and six of eleven patients having a partial response (PMID: 18451237).",col1a1-pdgfb,"{'id': 408, 'code': 'DFSP', 'color': 'Black', 'name': 'Dermatofibrosarcoma Protuberans', 'mainType': {'id': None, 'name': 'Skin Cancer, Non-Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Tretinoin,Tretinoin is FDA-approved for patients with relapsed or refractory acute promyelocytic leukemia characterized by the presence of PML-RARA gene expression or t(15,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,1850498,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on an open-label, uncontrolled single investigator clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC) and two cohorts of compassionate cases treated by multiple investigators under the National Cancer Institute (NCI) investigating tretinoin in patients with APL previously treated (n=114) and patients with untreated APL (""de novo"", n=67). In the previously treated patient cohorts, the complete response rate was 80% in the MSKCC cohort (16/20), 50% in NCI cohort 1 (24/48) and 52% in NCI cohort 2 (24/46). In the de novo patient cohorts, the complete response rate was 73% in the MSKCC cohort (11/15), 36% in NCI cohort 1 (5/14) and 68% in NCI cohort 2 (26/38). In a clinical study investigating tretinoin in eleven patients with APL, nine patients harboring PML-RARA fusions demonstrated complete remission in response to treatment (PMID: 1850498).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,Arsenic Trioxide,17) translocation.,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,11559723,,"Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). FDA approval is based on the open-label, single-arm trial Study PLRXAS01 investigating arsenic trioxide efficacy in patients with relapsed or refractory APL (n=40). In the Study PLRXAS01, 34 patients (85%) demonstrated complete response and the eighteen-month overall and relapse-free survival estimates were 66% and 56%, respectively (PMID: 11559723).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
PML-RARA Fusion,"Tretinoin,Arsenic Trioxide",,LEVEL_1,LEVEL_Fda2,APL with PML-RARA,,23841729,,"Tretinoin is an orally bioavailable retinoid that is FDA-approved for use in patients with PML-RARA fusion-positive acute promyelocytic leukemia (APL). Arsenic trioxide is an intravenously administered arsenical that is FDA-approved for use in patients with PML-RARA fusion-positive APL. In a randomized, multicenter phase III trial comparing the efficacy of tretinoin plus arsenic trioxide (n=77) versus tretinoin plus chemotherapy (n=79) in patients with newly diagnosed APL (n=162), the tretinoin plus arsenic trioxide cohort demonstrated a 100% complete remission rate, a 97% two-year event-free survival rate and a two-year overall survival rate of 99% (95% CI: 93, 100) while the tretinoin plus chemotherapy cohort demonstrated a 95% complete remission rate, an 82% two-year event-free survival rate and a two-year overall survival rate of 91% (95% CI: 86, 97) (PMID: 23841729).",pml-rara,"{'id': 260, 'code': 'APLPMLRARA', 'color': 'LightSalmon', 'name': 'APL with PML-RARA', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'AMLRGA', 'level': 5, 'tumorForm': 'LIQUID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,"Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib.",LEVEL_2,LEVEL_Fda3,Inflammatory Myofibroblastic Tumor,,"26020125,24670165",,"Ceritinib, a second-generation small molecule ALK inhibitor, is FDA-approved for the treatment of ALK-fusion positive non-small cell lung cancer (NSCLC) in patients with disease progression or intolerance to crizotinib. Soft Tissue Sarcoma NCCN guidelines indicate that ceritinib shows activity in inflammatory myofibroblastic tumors (IMTs) with ALK translocation (v2.2018). NCCN recommendation is based on a Phase I dose escalation trial of ceritinib in patients with ALK-altered advanced cancers in which one patient with ALK-altered IMT had a partial response to ceritinib treatment lasting 9.7 months (PMID: 24670165). In an additional Phase I trial of ceritinib in Japanese patients with ALK-rearranged advanced tumors, one patient with IMT had a partial response to treatment with ceritinib (PMID: 26020125).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Brigatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,27836716,,"Brigatinib is an orally available small molecule inhibitor of ALK that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). In a Phase I/II trial of brigatinib in patients with ALK-rearranged advanced malignancies, two patients with inflammatory myofibroblastic tumors (IMT) had stable disease and partial response, respectively (PMID: 27836716). The NCCN (Soft Tissue Sarcoma, v1.2021) lists brigatinib as a category 2A recommendation for patients with ALK-rearranged IMT.",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,"32868646,33007314,28713152",,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is FDA-approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer. The NCCN compendium lists lorlatinib as a category 2A recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a case report of an eighteen-year-old woman with pulmonary IMT with an unknown ALK gene rearrangement, the patient was treated with lorlatinib and demonstrated significant clinical response and disappearance of leptomeningeal carcinomatosis after three months of treatment (PMID: 28713152). In a second case report of a 40-year-old man with a TPM4-ALK fusion-positive IMT, the patient was treated with lorlatinib for eight months with partial response before his disease progressed at eleven months of treatment (PMID: 32868646). In a third case report, a 43-year-old woman with IMT of the bladder harboring an FN1-ALK gene fusion was treated with lorlatinib for five weeks with a rapid partial response before the patient complained of breathing issues and treatment was stopped (PMID: 33007314).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Alectinib,,LEVEL_2,LEVEL_Fda2,Inflammatory Myofibroblastic Tumor,,28586279,,"Alectinib is a second-generation small molecule inhibitor of ALK. The NCCN compendium lists alectinib as a recommendation for patients with ALK-rearranged inflammatory myofibroblastic tumors (IMT). In a randomized, open-label Phase III clinical trial of alectinib versus crizotinib in previously untreated patients with ALK-positive non-small-cell lung cancer (n=303), patients treated with alectinib (n=152) and patients treated with crizotinib (n=151) demonstrated a progression-free survival of 68.4% (95% CI: 61.0 to 75.9) and 48.7% (95% CI: 40.4 to 56.9), respectively (PMID: 28586279).",ALK,"{'id': 803, 'code': 'IMT', 'color': 'LightYellow', 'name': 'Inflammatory Myofibroblastic Tumor', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Selumetinib,,LEVEL_2,LEVEL_Fda2,Pilocytic Astrocytoma,,31151904,,"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",BRAF,"{'id': 407, 'code': 'PAST', 'color': 'Gray', 'name': 'Pilocytic Astrocytoma', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': 'ENCG', 'level': 3, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Erdheim-Chester Disease,,30867592,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",BRAF,"{'id': 611, 'code': 'ECD', 'color': 'LightSalmon', 'name': 'Erdheim-Chester Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Langerhans Cell Histiocytosis,,"32991018,30867592",,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",BRAF,"{'id': 862, 'code': 'LCH', 'color': 'LightSalmon', 'name': 'Langerhans Cell Histiocytosis', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_2,LEVEL_Fda3,Rosai-Dorfman Disease,,29236635,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",BRAF,"{'id': 367, 'code': 'RDD', 'color': 'LightSalmon', 'name': 'Rosai-Dorfman Disease', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'HDCN', 'level': 4, 'tumorForm': 'LIQUID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR1,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Pancreatic Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Pancreatic Adenocarcinoma Guidelines (V1.2025) under ""Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease: Useful in Certain Circumstances"" for patients with FGFR genetic alterations. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with pancreatic cancer (n=18 [n=4, FGFR1 fusion; n=14, FGFR2 fusion]) demonstrated an overall response response rate (ORR) of 56% (n=10 [n=2, FGFR1 fusion; n=8, FGFR2 fusion]) (95% CI=31-79), a median duration of response (DOR) of 7.1 months (95% CI=2.8-NE), a disease control rate (DCR) of 94% (95% CI=73-100), a median progression-free survival (PFS) of 7.0 months (95% CI=3.8-NE) and a median overall survival (OS) of 19.7 months (95% CI=9.9-NE)(PMID: 37541273).",FGFR2,"{'id': 899, 'code': '', 'color': 'Purple', 'name': '', 'mainType': {'id': None, 'name': 'Pancreatic Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Pancreas', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Bladder Cancer,,"37870920,31340094",,"Erdafitinib is an orally available, small molecule pan-FGFR inhibitor. Erdafitinib is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test. Susceptible FGFR3 alterations were identified through the QIAGEN therascreen FGFR RGQ RT-PCR kit and include FGFR3 fusions (FGFR3-TACC3_v1, FGFR3-TACC3_v3, FGFR3-BAIAP2L1) and FGFR3 hotspots (G370C, R248C, S249C, Y373C). For bladder cancer with other susceptible FGFR3 genetic alterations, the NCCN Bladder Cancer Guidelines recommend treatment with erdafitinib. FDA approval was based on the results of a Phase II trial of erdafitinib in 96 patients with FGFR-altered mUC in which the confirmed overall response rate was 42% (complete response, 3%; partial response, 37%) with a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. (PMID: 31340094). In the Phase III THOR trial of erdafitinib in 266 patients with FGFR3-mutated locally advanced or mUC who have had progression during or after treatment with checkpoint inhibitors, the erdafitinib treatment arm (n=136; n=25 patients harboring FGFR3 fusions, n=108 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=3 patients harboring both FGFR3 fusion and mutation) demonstrated a median OS of 12.1 months (95% CI=10.3 to 16.4), a median PFS of 5.6 months (95% CI=4.4 to 5.7) and an objective response rate of 45.6%, with a 6.6% (n=9) complete response rate and 39% (n=53) partial response rate, whereas the chemotherapy arm (n=130; n=19 patients harboring FGFR3 fusions, n=107 patients harboring FGFR3 G370C, R248C, S294C or Y373C, n=4 patients harboring both FGFR3 fusion and mutation) demonstrated a median overall survival of 7.8 months (95% CI=6.5 to 11.1) (HR=0.64 [95% CI=0.47 to 0.88]; P=0.005), a median PFS of 2.7 months (95% CI=1.8 to 3.7) (HR=0.58 [95% CI=0.44 to 0.78]; P<0.001) and an objective response rate of 11.5% (Relative benefit=3.94 [95% CI=2.37 to 6.57]; P<0.001), with a 0.8% (n=1) complete response rate and 10.8% (n=14) partial response rate (PMID: 37870920).",FGFR3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,37541273,,"Erdafitinib is an orally available, small molecule pan-FGFR targeted inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is recommended in the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines (V3.2025) under ""Emerging Biomarkers to Identify Novel Therapies for Patients With Metastatic NSCLC"" for patients with FGFR alterations that are oncogenic or likely oncogenic. NCCN recommendation is based on the results of the Phase II RAGNAR (NCT04083976) trial of erdafitinib in patients with FGFR1-3 mutated solid tumors.

In the Phase II RAGNAR (NCT04083976) trial, patients with squamous NSCLC (n=14 [n=2, FGFR2 alteration; n=12, FGFR3 alteration]) and non-squamous NSCLC (n=9 [n=5, FGFR2 alteration; n=4, FGFR3 alteration]) were treated with erdafitinib and demonstrated an overall response rate (ORR) of 21% (n=3 [n=1, FGFR3 mutation; n=2, FGFR3 fusion])(95% CI=5-51) and 33% (n=3 [n=1, FGFR2 fusion; n=1, FGFR2 mutation; n=1, FGFR3 fusion (complete response)]) (95% CI=8-70), respectively (PMID: 37541273). The squamous NSCLC and non-squamous NSCLC cohorts demonstrated median duration of responses (DOR) of 3.7 months (95% CI=2.3-NE) and 5.6 months (95% CI=2.8-NE), disease control rates (DCR) of 86% (95% CI=57-98) and 56% (95% CI=21-86), median progression-free survivals (PFS) of 4.1 months (95% CI=2.4-NE) and 4.1 months (95% CI=1.4-NE) and median overall survivals (OS) of 10.5 months (95% CI=2.4-14.6) and not evaluable (95% CI=2.3-NE), respectively (PMID: 37541273).",FGFR3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Ruxolitinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,Fedratinib,,LEVEL_2,LEVEL_Fda2,Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2,,"32279331,26202607,23630205,25260694",,"Ruxolitinib and fedratinib are small-molecule inhibitors of JAK1/2 and JAK2 kinases, respectively. The NCCN guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes (v3.2021) lists ruxolitinib and fedratinib as category 2A recommendations for patients with myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangements. In a study of ruxolitinib in nine patients with JAK2 fusion-positive myeloproliferative neoplasms (MPN), five patients had a transient complete hematological response to treatment with ruxolitinib (PMID: 32279331). Additionally, several case studies have documented clinical responses of patients with JAK2 fusion-positive MPN, though many of these responses were transient (PMID: 23630205, 26202607, 25260694).",JAK2,"{'id': 693, 'code': 'MLNER', 'color': 'LightSalmon', 'name': 'Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2', 'mainType': {'id': None, 'name': 'Leukemia', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Imatinib, (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,22718859,,"Imatinib, a small molecule inhibitor of KIT, PDGFRA and other kinases, is FDA-approved for adult patients with gastrointestinal stromal tumors (GISTs) and is an NCCN category 2A recommendation for the treatment of GISTs that are either 1) resectable but with a significant risk of morbidity or 2) unresectable, recurrent or metastatic. The NCCN guidelines state that most PDGFRA mutations, with the exception of the D842V mutation, are associated with a response to imatinib. NCCN recommendation is based on results of a clinical survey demonstrating that in 26 patients with GIST harboring PDGFRA mutation who were treated with imatinib (excluding PDGFRA D842V mutations), median progression-free survival was 28.5 months (95% CI= 5.4-51.6) and median overall survival was not reached (PMID: 22718859).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Sunitinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"17046465,25641662,19282169",,"Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases that is NCCN-listed and FDA-approved for patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. In a randomized, double-blind, placebo-controlled, multicenter, international, phase III trial (NCT00075218) of 312 patients with advanced imatinib-resistant/intolerant GIST who received either sunitinib (n=207 patients) or placebo (n=105 patients), the median time to tumor progression was 27.3 weeks (95% CI= 16.0–32.1) for patients receiving sunitinib and 6.4 weeks (95% CI= 4.4–10.0) for those on placebo (HR 0.33; p<0·0001) (PMID: 17046465). In a randomized, phase II study (NCT00137449) of sunitinib in 60 patients with imatinib-resistant/intolerant GIST, the clinical benefit rate was 53% (95% CI= 40–66), eight patients (13%) achieved objective partial responses, and 24 (40%) achieved stable disease ⩾24 weeks (PMID:19282169). In a worldwide treatment-use trial of sunitinib in 1,124 patients with imatinib-resistant/intolerant GIST, the median treatment duration was 7.0 months, the median time to tumor progression was 8.3 months (95% CI= 8.0–9.4), and median overall survival was 16.6 months (95% CI= 14.9–18.0), with 36% of patients alive at the time of analysis (PMID: 25641662).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Regorafenib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,"27371698,23177515",,"Regorafenib, a small molecule inhibitor of KIT and other kinases (e.g. VEGFR2 and -3, PDGFR), is FDA-approved for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. In a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT01271712) of 199 patients with imatinib and sunitinib-resistant, metastatic GIST that received regorafenib (n=133 patients) or placebo (n=66 patients), median progression-free survival (PFS) per independent blinded central review was 4.8 months (IQR 1.4–9.2) for regorafenib and 0.9 months (0.9–1.8) for placebo (HR= 0.27; 95% CI= 0.19–0.39; p<0·0001) and following progression, 56/66 patients (84.8%) on placebo crossed over to regorafenib, resulting in no significant difference in overall survival (OS) between study arms (HR= 0.77; 95% CI= 0.42–1.41; p=0.199) (PMID: 23177515). In a multicenter, open-label, phase II trial (NCT01068769) of regorafenib in 33 adult patients with imatinib- and sunitinib-resistant metastatic GIST, the clinical benefit rate was documented in 25/33 patients (76%; 95% CI= 58-89), including six partial responses; the median PFS was 13.2 months (95% CI= 9.2–18.3 months), including four patients who remained progression-free at study closure, each achieving clinical benefit for more than three years (range 36.8–43.5 months); and the median OS was 25 months (95% CI= 13.2–39.1 months) (PMID: 27371698).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Ripretinib,,LEVEL_2,LEVEL_Fda2,Gastrointestinal Stromal Tumor,,32511981,,"Ripretinib is a small molecule inhibitor of KIT and PDGFRA kinases that is FDA-approved for adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors. FDA approval was based on the results of the international, multi-center, randomized (2:1), double-blind, placebo-controlled trial (NCT03353753) of ripretinib in 129 patients with advanced, pretreated GIST in which the overall response rate was 9% (95% CI= 4.2, 18), the median progression-free survival was 6.3 months (95% CI= 4.6, 6.9), and the median overall survival was 15.1 months (95% CI= 12.3, 15.1) (PMID: 32511981).",PDGFRA,"{'id': 968, 'code': '', 'color': 'LightYellow', 'name': '', 'mainType': {'id': None, 'name': 'Gastrointestinal Stromal Tumor', 'tumorForm': 'SOLID'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cabozantinib,Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,"23533264,27825636,28447912",,"Cabozantinib is a small molecule inhibitor of several receptor tyrosine kinases including RET, MET and VEGFR2 that is FDA-approved for use in patients with advanced renal cell carcinoma (RCC) and is NCCN recommended as category 2A in patients with non-small cell lung cancer (NSCLC) harboring RET rearrangements. Cabozantinib has demonstrated activity in advanced lung adenocarcinoma with RET translocations (PMID: 23533264). NCCN recommendation is based on the results of an open-label Phase II trial of cabozantinib in patients with RET fusion-positive NSCLC in which seven of 25 response-assessable patients had a partial response to treatment (overall response rate = 28%) while the remaining eighteen patients had stable disease with a mean progression-free survival of 5.5 months (PMID: 27825636). Of the patients in the Phase II trial who had a partial response, three had KIF5B-RET fusions, one had a TRIM3-RET fusion, one had a CLIP1-RET fusion, and two had FISH-positive RET fusions with unknown partners (PMID: 27825636). Results from the global, multicenter RET registry demonstrated that of 21 RET fusion-positive patients with NSCLC who were treated with cabozantinib, one patient had a complete response, six patients had partial response and five patients had stable disease (PMID: 28447912).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Ceritinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,28520527,,"Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Lorlatinib,,LEVEL_2,LEVEL_Fda2,Non-Small Cell Lung Cancer,,31669155,,"Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",ROS1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Bosutinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"25132497,24345751,26040495",,"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). Bosutinib demonstrated acceptable tolerability in a phase I/II trial (NCT00261846) of 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, and while responses were observed among some patients, analyses of these data were limited by the small number of ALL patients (PMID: 26040495, 24345751). Cell proliferation assays performed with Ba/F3 cells expressing native BCR-ABL1 demonstrated sensitivity to bosutinib, exhibiting IC50 values <150 nM (PMID: 25132497).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
BCR-ABL1 Fusion,Nilotinib,,LEVEL_2,LEVEL_Fda2,B-Lymphoblastic Leukemia/Lymphoma,,"16775235,26065651",,"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy, and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In a phase I dose-escalation study (NCT00109707) of nilotinib in thirteen patients with Ph+ ALL, one patient had a partial hematologic response and another had a complete molecular remission (PMID: 16775235). In a separate phase II, multicenter, single-arm study (NCT00844298) combining nilotinib with multiagent chemotherapy in 90 evaluable adult patients with Ph+ ALL undergoing chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT, n = 57 patients), the complete hematologic remission (HCR) rate was 91%, the two-year hematologic relapse-free survival rate was 72% for the 82 subjects that achieved HCR, and the two-year overall survival rate was 72% (PMID 26065651).",bcr-abl1,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,NVL-655,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,39269178,https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext,"NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK-rearranged non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 103 patients with ALK-rearranged NSCLC, the overall response rate (ORR) was 38% (39/103) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=85) or were lorlatinib-naïve (n=17), the ORR was 35% (30/85) and 53% (9/17), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178).",ALK,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations (excluding V600),Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Trametinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Melanoma,,"26314551,24345920,33861486,26072686",,"Cobimetinib and trametinib are orally available, small-molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. There is promising clinical data in patients with BRAF fusion-positive melanoma treated with cobimetinib and trametinib monotherapies.
Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In the Phase II VICC MEL 1457 (NCT02296112) trial of trametinib in patients with BRAF non-V600 mutant metastatic melanoma (n=2, patient with BRAF fusion), one patient harboring a BRAF-AGAP3 fusion achieved a partial response with an on-going progression-free survival of 1.8 months and one patient harboring a BRAF-MZT1 fusion demonstrated progressive disease (PMID: 33861486).
In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 453, 'code': 'MEL', 'color': 'Black', 'name': 'Melanoma', 'mainType': {'id': None, 'name': 'Melanoma', 'tumorForm': 'SOLID'}, 'tissue': 'Skin', 'children': {}, 'parent': 'SKIN', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Cobimetinib,,LEVEL_3A,LEVEL_Fda3,Ovarian Cancer,,"24345920,26324360",,"Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",BRAF,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations (excluding V600),Trametinib,,LEVEL_3A,LEVEL_Fda3,Histiocytosis,,30361829,,"Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",BRAF,"{'id': 934, 'code': '', 'color': 'LightSalmon', 'name': '', 'mainType': {'id': None, 'name': 'Histiocytosis', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'LIQUID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_3A,LEVEL_Fda3,Cholangiocarcinoma,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small-molecule FGFR2 tyrosine kinase inhibitor. There are promising clinical data of response to lirafugratinib in patients with FGFR2-mutated cholangiocarcinoma (CCA). In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I, one patient with FGFR2-FLIP1 fusion-positive CCA and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) and FGFR2 fusions demonstrate sensitivity to lirafugratinib as measured by inhibition of cellular proliferation (PMID: 37270847).",FGFR2,"{'id': 283, 'code': 'CHOL', 'color': 'Green', 'name': 'Cholangiocarcinoma', 'mainType': {'id': None, 'name': 'Hepatobiliary Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Biliary Tract', 'children': {}, 'parent': 'BILIARY_TRACT', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Seribantumab,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,,https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006,"Seribantumab is a monoclonal antibody against the HER3 protein that targets NRG1 signaling. In the Phase II CRESTONE trial of seribantumab in NRG1 fusion-positive solid tumors, the overall response rate in patients with non-small cell lung cancer (NSCLC; n=11) was 36%, with two of eleven patients achieving a complete response, two of eleven patients achieving a partial response, and seven of eleven patients achieving stable disease (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006). For the NSCLC cohort, the disease control rate was 91% (Abstract: Carrizosa et al. Abstract# 3006, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006).",NRG1,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Fusions,Zenocutuzumab,,LEVEL_3A,LEVEL_Fda3,All Solid Tumors,,39908431,,"Zenocutuzumab is an intravenously infused, anti-HER2/HER3 antibody that is FDA-approved for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. There are promising clinical data for zenocutuzumab for the treatment of patients with NRG1 fusion-positive solid tumors. 
In the Phase II eNRGy study (NCT02912949) of zenocutuzumab in 161 patients with advanced NRG1 fusion-positive solid tumors [pancreatic cancer (n=36), NSCLC (n=94), breast cancer (n=9), cholangiocarcinoma (n=10), colorectal cancer (n=6), cancer of unknown primary (n=2), other solid tumor types (n=4)], the overall response rate (ORR) was 31% (95% CI=24-39), including responses in NSCLC (31%; 29/94), pancreatic cancer (44%; 16/36), cholangiocarcinoma (1 partial response [PR]), gastric cancer (1 PR) and ovarian cancer (1 PR) (PMID: 39908431).",NRG1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Pralsetinib,,LEVEL_3A,LEVEL_Fda3,Medullary Thyroid Cancer,,29657135,"https://meetinglibrary.asco.org/record/174787/abstract)(Abstract,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy","Pralsetinib is a small-molecule inhibitor of RET kinase. As of 7/30/2023 the FDA has withdrawn the approval of pralsetinib for the treatment of patients with RET-mutant medullary thyroid cancer (MTC) (https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals). In the Phase I dose-escalation study of pralsetinib in patients with advanced, unresectable non-small cell lung cancer, thyroid cancer, or other solid tumors, one patient with RET-mutant medullary thyroid cancer (MTC) (RET L629P, D631_R635DELINSG, and V637R) achieved a confirmed partial response (47% maximal reduction) after ten months of treatment with pralsetinib, and a second patient with RET M918T-mutant MTC who responded and then progressed on vandetanib had a confirmed partial response at eight months (maximum 47% reduction) of treatment with pralsetinib (PMID: 29657135). In vitro studies demonstrated that pralsetinib inhibits cabozantinib-resistant KIF5B-RET V804L-mutant cell lines in vitro in xenograft models (PMID: 29657135) (Abstract: Taylor et al. Abstract# 6018, ASCO 2019. https://meetinglibrary.asco.org/record/174787/abstract)(Abstract: Hu et al. Abstract# 19130, ESMO 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy).",RET,"{'id': 495, 'code': 'THME', 'color': 'Teal', 'name': 'Medullary Thyroid Cancer', 'mainType': {'id': None, 'name': 'Thyroid Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Thyroid', 'children': {}, 'parent': 'THYROID', 'level': 2, 'tumorForm': 'SOLID'}"
Fusions,Vandetanib,,LEVEL_3A,LEVEL_Fda3,Non-Small Cell Lung Cancer,,27803005,,"Vandetanib is a multi-tyrosine kinase inhibitor that has activity against VEGFRs, EGFR and RET in pretreated patients with advanced non-small cell lung cancer (NSCLC) with RET rearrangements. In a multi-center, open-label, phase II clinical trial of vandetanib (NCT01823068) in seventeen evaluable patients with metastatic or recurrent NSCLC with a RET rearrangement, three had a partial response (objective response rate = 18%), eight had stable disease (disease control rate = 65%), the median progression-free survival was 4.5 months, and median overall survival was 11.6 months with a median follow-up of fourteen months (PMID: 27803005).",RET,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR1-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR1-amplified (n=17) and FGFR1-rearranged (n=1) tumors in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, eight patients demonstrated stable disease (SD) (n=7, FGFR1 amplification; n=1, FGFR1-BAG4) and six patients demonstrated progressive disease (PD) (n=6, FGFR1 amplification) (PMID: 32463741). 

In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Lirafugratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,37270847,https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R,"Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-mutated solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). In FGFR2-altered CCA patient cases from the Phase I/II ReFocus (NCT04526106) trial, one patient with FGFR2-WAC fusion-positive CCA harboring FGFRi resistance mutations FGFR2 N549K, N549D and V564I and one patient with metastatic salivary gland carcinoma harboring FGFR2 Y375C were treated with lirafugratinib and achieved partial responses (PMID: 37270847). Preclinical studies of FGFR2 fusion-positive CCA cell lines and models expressing FGFR2 resistance mutations (FGFR2 V564F, N549D, V564L, N549K, V564I, E565A, L617V, N549H, M537I, K641N and K659M) demonstrates sensitivity to lirafugratinib as measured by tumor regression and decreased cellular viability (PMID: 37270847).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",,"Fexagratinib and erdafitinib are orally available, small molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support use of fexagratinib and erdafitinib monotherapies in patients with FGFR2-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR2-mutated tumors (n=12) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR2 Y367C), two patients demonstrated stable disease (SD) (n=2, FGFR2 S252W), and seven patients demonstrated progressive disease (PD) (n=1, FGFR2 S252W; n=2, FGFR2 K660E; n=1, FGFR2 C383R; n=1, FGFR2 N550D; n=1, FGFR2 N550K [c.1650T>G]; n=1, FGFR2 N550K [c.1650T>A]) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831).",FGFR2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Erdafitinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Oncogenic Mutations,Fexagratinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"31088831,32463741",https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571,"Fexagratinib and erdafitinib are orally available, small-molecule FGFR1-4 tyrosine kinase inhibitors. There are promising laboratory and anecdotal clinical data to support the use of fexagratinib and erdafitinib monotherapies in patients with FGFR3-mutated solid tumors. In the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial of fexagratinib for 48 patients with FGFR-altered (n=20, FGFR1/2 amplification; n=19, FGFR2/3 single-nucleotide variants (SNV); n=9, FGFR1/3 fusions) refractory cancers, lymphomas or myelomas (33.3% breast; 12.5% urothelial; 10.4% cervical; 8.3% endometrial; 35.5% other rare malignancies), the median progression-free survival (PFS) was 3.4 months, the six-month PFS rate was 15% (90% CI=8-31) and the overall response rate (ORR) was 8% (90% CI=3-18), with four partial responses (PR) (n=1, FGFR2 Y376C; n=1, FGFR3 A393E; n=2, FGFR3-TACC3), in all evaluable patients (PMID: 32463741). Of patients with FGFR3-mutated tumors (n=7) in the Phase II NCI-MATCH (EAY131) Subprotocol W (NCT02465060) trial, one patient demonstrated PR (n=1, FGFR3 A393E), two patients demonstrated stable disease (SD) (n=2, FGFR3 S249C), and three patients demonstrated progressive disease (PD) (n=2, FGFR3 S249C; n=1, FGFR3 R248C) (PMID: 32463741). In the Phase I (NCT01703481) trial of erdafitinib in 187 patients with advanced solid tumors (19% breast; 16% urothelial; 13% non-small cell lung; 7% glioblastoma; 6% cholangiocarcinoma, ovarian, head and neck; 1% gastric; 26% other), the ORR was 11% (95% CI=7-17), with an 11% (n=21) PR rate, 16% (n=29) SD rate and 56% (n=104) PD rate in all evaluable patients (PMID: 31088831). Of patients with FGFR-mutated solid tumors (n=92 [n=11, cholangiocarcinoma; n=13, glioblastoma; n=27, urothelial; n=20, non-small cell lung; n=29, breast; n=8, ovarian; n=6, head and neck; n=1 gastric; n=20, other]), the ORR was 21% (95% CI=13-30), with a 21% (n=19) PR rate, 21% (n=19) SD rate and 50% (n=46) PD rate (PMID: 31088831). In an analysis of the UNITE study for erdafitinib in 39 patients with FGFR2/3-altered metastatic urothelial cancer (n=33, canonical FGFR2/3 mutations [FGFR3 S249C, FGFR3 Y373C, FGFR3 R248C, FGFR3-TACC3 fusion]; n=6, non-canonical FGFR2/3 mutations [FGFR3 A248C, FGFR3 A391E, FGFR2 Y375C, FGFR3 V555L, FGFR2 T807L, JAKMIP1-FGFR3 fusion]), there were no significant differences in the PFS (HR=0.8 [95% CI=0.29-2.3]; p=0.66), the overall survival (HR=0.4 [95% CI=0.06-2.3]; p=0.086) or the ORR (OR=2.1 [95% CI=0.27-27.7]; p≥0.99) between the canonical and non-canonical FGFR2/3 mutation cohorts (Abstract: Jiang et al. ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16571).",FGFR3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Crizotinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,"29284707,29102694,29527595",http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539,"Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707).",MET,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 fusions may be sensitive to zurletrectinib. Preclinical studies with LMNA-NTRK1-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK1,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK2 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK2-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
Fusions,Zurletrectinib,,LEVEL_4,LEVEL_Fda3,All Solid Tumors,,38902532,,"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK3 fusions may be sensitive to zurletrectinib. Preclinical studies with ETV6-NTRK3-rearranged cell lines and xenograft models demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532).",NTRK3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 551, 'code': 'ES', 'color': 'White', 'name': 'Ewing Sarcoma', 'mainType': {'id': None, 'name': 'Bone Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bone', 'children': {}, 'parent': 'BONE', 'level': 2, 'tumorForm': 'SOLID'}"
EWSR1-FLI1 Fusion,TK216,,LEVEL_4,LEVEL_Fda3,Ewing Sarcoma of Soft Tissue,,"19584866,38954782",http://cancerres.aacrjournals.org/content/77/13_Supplement/694,"TK216 is a first-in-class, small molecule inhibitor of the EWS-FLI1 fusion protein, which is expressed in Ewing sarcoma family tumors. Specifically, TK216 blocks RNA helicase A binding to EWS-FLI1 and impacts alternative splicing in a manner similar to EWS-FLI1 knockdown in Ewing sarcoma cell lines. In vitro and in vivo cell line and orthotopic xenograft studies show that Ewing sarcoma tumors are sensitive to TK216 as measured by decreased cell proliferation and tumor growth upon drug treatment (PMID: 19584866)(Abstract: Selvanathan et al. Abstract# 694, AACR 2017. http://cancerres.aacrjournals.org/content/77/13_Supplement/694). In an open-label phase I/II trial (NCT02657005) of TK216 in patients with relapsed or refractory Ewing Sarcoma with any mutational status (n=85), three patients had an extraordinary response (complete response, n=2; partial response, n=1), the disease control rate was 24.7% and the median duration of response was 25 months (95% CI, 1.1-35.2) (PMID: 38954782).",ewsr1-fli1,"{'id': 284, 'code': 'ESST', 'color': 'LightYellow', 'name': 'Ewing Sarcoma of Soft Tissue', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'SOFT_TISSUE', 'level': 2, 'tumorForm': 'SOLID'}"
